Table 2.
Absolute values (and standard deviations) for percentages of grey and white matter and cerebrospinal fluid in the voxels of interest
| Voxel | Drug | Tissue | TD | ASD | F(dof) | p-value |
|---|---|---|---|---|---|---|
| BG | PLC | GM | 42.53% (3.03%) | 45.43% (3.21%) | F(1) = 7.307 | p = 0.011 |
| WM | 50.47% (3.39%) | 46.54% (4.08%) | F(1) = 9.345 | p = 0.004 | ||
| CSF | 6.92% (1.33%) | 7.95% (1.95%) | F(1) = 3.222 | p = 0.082 | ||
| CBD | GM | 43.24% (3.54%) | 45.07% (3.64%) | F(1) = 2.157 | p = 0.152 | |
| WM | 49.20% (4.66%) | 47.29% (4.32%) | F(1) = 1.482 | p = 0.233 | ||
| CSF | 7.46% (2.16%) | 7.56% (1.93%) | F(1) = 0.19 | p = 0.890 | ||
| DMPFC | PLC | GM | 52.93% (2.21%) | 52.38% (3.49%) | F(1) = 0.299 | p = 0.589 |
| WM | 27.24% (3.36%) | 28.11% (3.65%) | F(1) = 0.527 | p = 0.473 | ||
| CSF | 19.73% (4.05%) | 19.41% (2.57%) | F(1) = 0.076 | p = 0.784 | ||
| CBD | GM | 52.69% (2.86%) | 52.84% (3.69%) | F(1) = 0.017 | p = 0.898 | |
| WM | 27.32% (3.54%) | 27.41% (4.14%) | F(1) = 0.004 | p = 0.947 | ||
| CSF | 19.89% (3.72%) | 19.63% (2.53%) | F(1) = 0.048 | p = 0.827 |
Significant between-group differences are highlighted in bold
ASD autism spectrum disorder, BG basal ganglia, CBD cannabidiol, CSF cerebrospinal fluid, DMPFC dorsomedial prefrontal cortex, F(dof) F statistic and degrees of freedom, GM grey matter, PLC placebo, TD typically developing individuals, WM white matter